Who are AGN-241751's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Medium-dose anrikefon, Flecainide controlled release, Propafenone i.v., TAK-816, Group VTI, Flecainide Injectable Solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/agn-241751.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AGN-241751 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AGN-241751 (AGN-241751) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sodium-activated potassium channel inhibitor. Area: Cardiovascular.

phase 2 Sodium-activated potassium channel inhibitor Nav1.5 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

AGN-241751 (AGN-241751) — Syndeio Biosciences, Inc. AGN-241751 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AGN-241751 TARGET	AGN-241751	Syndeio Biosciences, Inc	phase 2	Sodium-activated potassium channel inhibitor	Nav1.5
Medium-dose anrikefon	Medium-dose anrikefon	Peking University First Hospital	marketed	Sodium channel blocker	Nav1.5
Flecainide controlled release	Flecainide controlled release	MEDA Pharma GmbH & Co. KG	marketed	Class IC antiarrhythmic agent	Cardiac voltage-gated sodium channel (Nav1.5)
Propafenone i.v.	Propafenone i.v.	Charles University, Czech Republic	marketed	Class IC antiarrhythmic agent	Cardiac sodium channel (Nav1.5)
TAK-816	TAK-816	Takeda	phase 3	Sodium-activated potassium channel inhibitor	Nav1.5
Group VTI	Group VTI	Kasr El Aini Hospital	phase 3	sodium-activated potassium channel inhibitor	Nav1.5
Flecainide Injectable Solution	Flecainide Injectable Solution	Hippocration General Hospital	phase 3	Class IC antiarrhythmic agent	Cardiac voltage-gated sodium channel (Nav1.5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sodium-activated potassium channel inhibitor class)

Chiesi Farmaceutici S.p.A. · 1 drug in this class
Chong Kun Dang Pharmaceutical · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Mylan Inc. · 1 drug in this class
Pfizer · 1 drug in this class
Syndeio Biosciences, Inc · 1 drug in this class
Takeda · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AGN-241751 — Competitive Intelligence Brief. https://druglandscape.com/ci/agn-241751. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing